

Agenda/Minutes
The Institutional Biosafety Committee (IBC) Meeting
Albany Medical College

July 9, 2026

Time: 2:00PM-2:46PM

Webex

IBC Members Present:

Member Name	Type	Voting
Kevin Pumiglia, Ph.D., IBC Chair, Department of Regenerative and Cancel Cell Biology	☒ Affiliated ☐ Unaffiliated ☐ Scientist ☐ Nonscientist ☐ Alt	☒ Yes ☐ No
David M. Chico, VMD, MPH, DACVPM, NYS Department of Agriculture and Markets, Division of Animal Industry	☐ Affiliated ☒ Unaffiliated ☐ Scientist ☐ Nonscientist ☐ Alt	☒ Yes ☐ No
Carlos de Noronha, Ph.D., ARO, Department of Immunology and Microbial Disease	☒ Affiliated ☐ Unaffiliated ☐ Scientist ☐ Nonscientist ☐ Alt	☒ Yes ☐ No
Karsten R. O. Hazlett, Ph.D. Department of Regenerative and Cancel Cell Biology	☒ Affiliated ☐ Unaffiliated ☐ Scientist ☐ Nonscientist ☐ Alt	☒ Yes ☐ No
John Lamar, Ph.D., Assistant Professor, Department of Molecular and Cellular Physiology	☒ Affiliated ☐ Unaffiliated ☐ Scientist ☐ Nonscientist ☐ Alt	☒ Yes ☐ No
Anthony May, D.V.M., DACLAM, DACVPM, Director/Attending Veterinarian Animal Resources Facility	☒ Affiliated ☐ Unaffiliated ☐ Scientist ☐ Nonscientist ☐ Alt	☒ Yes ☐ No
Nil McManus, RO, IBSO, Director of Environmental Health and Safety	☒ Affiliated ☐ Unaffiliated ☐ Scientist ☐ Nonscientist ☐ Alt	☒ Yes ☐ No

Julia Nalwalk, Instructor, Department of Neuroscience and Experimental Therapeutics	☒ Affiliated ☐ Unaffiliated ☐ Scientist ☐ Nonscientist ☐ Alt	☒ Yes ☐ No
---	--	--

Quorum:

The IBC has eleven (11) voting members of whom 8 were present when the meeting convened at 2:06PM. Quorum was maintained throughout the business of the meeting.

Other Individuals in Attendance:

Call to Order: The IBC Chair called the meeting to order at 2:06PM

- Meeting Minutes of** February 12, 2026 were Approved on March 17, 2026
(Approval of minutes is conducted electronically via email)

Vote: Total 9 Yes 9 No 0 Abstain 2

- Conflicts of Interest** - The Chair will ask the members to disclose any potential or actual conflict of interest with any registration to be reviewed at today's meeting.

☒ No conflicts were disclosed.

☐ One or more conflicts were disclosed. *committee member(s) name(s)*

- New IBC Registrations and Amendments for Review: None**

PI Name(s):

Registration Number/Title:

Project Overview:

NIH Guidelines Section:

Risk Assessment and Discussion:

Training:

Occupational Health Representative review (if applicable):

Biosafety Level Assignment:

IBC Vote: A motion was made and seconded to **Choose an item.**

Vote: Total Choose an item.; **Yes** Choose an item.; **No** Choose an item.; **Abstain** Choose an item.

Conflict(s) of Interest: *committee member(s) name(s)*

- Review of Prior Business: None**

- New Business/Additional Topics:**

- Red pod BSL-2 mice – Dr. Anthony May

- Mice from the BSL-2 infected with human tumor cells are being removed from their home cage, placed in clean cages, then taken to a PI's laboratory to be euthanized. The empty cages are then placed in red biohazard bags and returned to the dirty side cage wash in the ARF. This is something that has been going on for a while, but we just learned about it and wanted to get the committee's input.

The chair said he thought this was raised previously as an informal committee discussion. PIs can't be expected to do all their work in the BSL-2 red pod since there is no necropsy facility nor the equipment required to manipulate tissue and do cell cultures. And in this case, it's human tumor cells and the transport with oversight, placarding and biosafety level two precautions are already in place. Infectious agents are also probably fine in most cases because labs have their BSL-2 precautions, but we probably want to know what the agents are and there should be some level of review or oversight before they can be removed from the red pod and taken to PI's labs.

A committee member asked if the ARF staff who would be handling the cages know that the cages in the red hazard bags are BSL-2. Dr. May said he would speak with the ARF staff to get their input, make sure they are comfortable with it, and understand why this is being allowed.

Another committee member said from an infectious disease perspective, they are sure there are people who will bring things out of the red pod and up to the lab, but the mice don't come back down so don't think there's a need for additional regulation or oversight on that, and with the tumor cells don't think anything more is needed either.

6. Review of Incidents: None

7. Inspections/Ongoing Oversight:

- **CDC Renewal inspection March 24-26 – The Biological Safety Officer gave the following report.**
 - In total, there were five items the CDC put in the report. Four of them were departures, which the CDC ranks as severe, moderate, and low. We had one moderate and three low. The fifth was a general concern which is an item they raise for us to monitor, assess, and keep an eye on for process improvement but requires no additional response from us.
 - Moderate departure: A tissue digester used for decontamination was not confirmed to be operating correctly in 2025.
 - Response: Validation was delayed by a disruption in chemical supply. This has been resolved and the equipment has been validated.
 - Low departure: A laboratory chair had severe corrosion, impeding cleaning and decontamination.
 - Response: The chair has been tagged and removed from use. It will be replaced and disposed of during the annual facility shutdown once it has been decontaminated.
 - Low departure: The incident response plan did not include places of refuge for shelter-in-place emergencies.
 - Response: The institution's overarching Emergency Operations Plan provides incident-specific plans for managing events that could disrupt operations, and personnel follow institutional and facility response plans. The incident

response plan has been revised to better capture shelter-in-place and evacuation procedures.

- Low departure: A visitor entry log did not capture the time of entry for one escorted individual.
 - Response: It was confirmed that no active work was underway in the laboratory at the time. The individual was contacted, and access-and-escort training was completed and documented; it will be incorporated into facility reopening training. A reminder of the policy will be circulated to relevant personnel.
- General concern: During HVAC failure testing, transient positive-pressure readings were observed at some doors, with no air-flow reversals across the containment boundary. CDC recommended identifying the cause and confirming the readings through additional verification testing.
 - The Biological Safety Officer noted that recertification testing attributed the brief readings to a momentary, negligible effect that occurs as dampers close, and confirmed that no air-flow reversal occurs across the containment boundary. Continuous monitoring, backup power, and routine shutdown testing are in place to maintain containment, and the system performs as designed.
- CDC closed the inspection as satisfactory with no additional request for information needed.
- **BSL-3 shutdown update – The Biological Safety Officer gave the following update.**
 - Decontamination of the facility is complete, with results confirming it is clear. Facilities maintenance is expected to take two to three weeks, after which third-party vendors will perform recertification and quality checks and address any outstanding items. Required shutdown and system-performance testing will be conducted as part of the scheduled maintenance. The team is working to complete the process within approximately one month.

8. IBC Training:

- The annual Biosafety training module in Qualtrics will go out this month.

9. Public Comments: None

The Following Items are Informational Only:

10. Registrations/Significant Amendments Approved, Conditionally Approved, Disapproved, Tabled, or Terminated:

(IBC #116) Endothelial Functions of MEF2A and MEF2C in Cardiovascular Development (BSL-1) ...**Terminated and Archived on 02/11/2026.**

(IBC #190) MEF2 regulation of vascular homeostasis and angiogenesis (BSL-1) ...**Terminated and Archived on 02/11/2026.**

(IBC #205) RESQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer (BSL-2) ...**Approved on 02/20/2026.**

(IBC #32) Regulation of endothelial cell function by adherens junctions (BSL-2)... **Terminated and Archived on 04/30/2026.**

(IBC #50) Regulation of endothelial barrier function by inflammatory mediators (BSL-2)... **Terminated and Archived on 04/30/2026.**

11. Annual Updates/Amendments Approved by Chair and Biological Safety Officer:

(IBC #71) Molecular Mechanisms of Smooth Muscle Function (BSL-1)...*Request for Continuation and to Amend Registration* to include personnel: **Approved on 02/10/26.**

(IBC #123) p53 in cancer and metabolism (BSL-2)...*Request for Continuation*: **Approved on 02/10/26.**

(IBC #202) Targeted degradation in intracellular tau (BSL-1)...*Request for Continuation*: **Approved on 02/10/26.**

(IBC #149) Anatomical Simulation Center (BSL-2)...*Request to Amend Registration* to include room and personnel: **Approved on 02/19/26.**

(IBC #160) Vaccines against *Pseudomonas aeruginosa* and *Staphylococcus aureus* (BSL-2)...*Request for Continuation and to Amend Registration* to include personnel: **Approved on 02/19/26.**

(IBC #176) Identification and characterization of host factors associated with SARS-CoV2 replication in vitro (BSL-3)...*Request for Continuation*: **Approved on 02/19/26.**

(IBC #166) Host-pathogen interactions in inflammation and immunity during Tuberculosis infection (BSL-2)...*Request for Continuation*: **Approved on 03/03/26.**

(IBC #167) Host-pathogen interactions in inflammation and immunity during Tuberculosis infection (BSL-3)...*Request for Continuation*: **Approved on 03/03/26.**

(IBC #21) Signal Transduction in Macrophages (BSL-2)...*Request for Continuation and to Amend Registration* to include personnel: **Approved on 03/13/26.**

(IBC #98) The mTOR pathway in epileptogenesis. The role of eIF5A hypusination in neurodegeneration (BSL-2)...*Request for Continuation and to Amend Registration* to include personnel: **Approved on 03/13/26.**

(IBC #145) Pathological Glutamate Release in Stroke and Hyponatremia (BSL-2)...*Request for Continuation*: **Approved on 03/13/26.**

(IBC #193) Elucidating the structure of heparan sulfate co-receptor in SARS-CoV-2 infection (BSL-2)...*Request for Continuation and to Amend Registration* to include personnel: **Approved on 03/13/26.**

(IBC #194) Elucidating the structure of heparan sulfate co-receptor in SARS-CoV-2 infection (BSL-3)...*Request for Continuation*: **Approved on 03/13/26.**

(IBC #202) Targeted degradation of intracellular tau (BSL-1)...*Request to Amend Registration* to include personnel: **Approved on 03/25/26.**

(IBC #199) Transcription-driven epigenetics changes as a mechanism of severe inflammation sequelae (BSL-2)...*Request to Amend Registration* to include personnel and human tissue samples: **Approved on 03/31/26.**

(IBC #31) Role of Alpha3 Beta1 Integrin in EMT and Tumor Progression-in vivo Studies (BSL-2)...*Request for Continuation and to Amend Registration* to include personnel: **Approved on 05/01/26.**

(IBC #38) Role of Alpha3 Beta1 Integrin in EMT and Tumor Progression (BSL-2)...*Request for Continuation and to Amend Registration* to include personnel: **Approved on 05/01/26.**

(IBC #61) BCR Modulation of MHC Class II Structure and Function (BSL-1)...*Request for Continuation*: **Approved on 05/01/26.**

(IBC #87) Francisella outer membrane proteins (BSL-2)...*Request for Continuation*: **Approved on 05/01/26.**

(IBC #124) Targeting the foam cell to prevent atherosclerosis (BSL-2)...*Request for Continuation*: **Approved on 05/01/26.**

(IBC #146) Grant #293017: Collagen-remodeling genes provide a niche for ovarian cancer stem cells (BSL-2)...*Request for Continuation*: **Approved on 05/01/26.**

(IBC #199) Transcription-driven epigenetics changes as a mechanism of severe inflammation sequelae (BSL-2)...*Request to Amend Registration to include* host-vector, viral vector, animal use: **Approved on 05/01/26.**

(IBC #19) Calcium/Calmodulin Activated Kinases in Smooth Muscle (BSL-2)...*Request for Continuation and to Amend Registration to include* personnel: **Approved on 05/05/26.**

(IBC #35) Mechanisms for Hypoxic Calcium Release in Pulmonary Artery Myocytes (BSL-2)...*Request for Continuation*: **Approved on 05/05/26.**

(IBC #183) Project 1: The impact of aging on the functional and anatomical coupling between brainstem noradrenergic neurons and upper airway muscles (BSL-1)...*Request for Continuation and to Amend Registration to include* personnel: **Approved on 05/13/26.**

(IBC #205) RESQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer (BSL-2) ...*Request to Amend Registration to include* personnel and SOP: **Approved on 05/19/2026.**

(IBC #51) Matrix Mediators of Wound Healing (BSL-2)...*Request for Continuation*: **Approved on 06/02/26.**

(IBC #113) c-di-NMP responsive gene regulation and pathogenesis of Mycobacterium tuberculosis (BSL-2)...*Request for Continuation*: **Approved on 06/02/26.**

(IBC #172) Anatomy Plastination Laboratory (BSL-2)...*Request for Continuation*: **Approved on 06/02/26.**

(IBC #182) Morphologic, Immunohistochemical and Molecular Evaluation of Gastrointestinal, Liver, and Pancreatobiliary Disease (BSL-2)...*Request for Continuation*: **Approved on 06/02/26.**

(IBC #196) Morphologic, Immunohistochemical and Molecular Evaluation of Breast Disease (BSL-2)...*Request for Continuation*: **Approved on 06/02/26.**

(IBC #199) Transcription-driven epigenetics changes as a mechanism of severe inflammation sequelae (BSL-2)...*Request for Continuation and to Amend Registration to include* personnel: **Approved on 06/02/26.**

(IBC #183) Project 1: The impact of aging on the functional and anatomical coupling between brainstem noradrenergic neurons and upper airway muscles (BSL-1)...*Request to Amend Registration to include* personnel: **Approved on 06/03/26.**

(IBC #185) Morphologic, Immunohistochemical and Molecular Evaluation of Genitourinary Disease (BSL-2)...*Request for Continuation*: **Approved on 06/03/26.**

(IBC #205) RESQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer (BSL-2) ...*Request to Amend Registration to include* SOP amendment: **Approved on 06/03/2026.**

(IBC # 201) EG70-101 A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) and High-Risk NMIBC

Patients who are Naïve or Received Incomplete BCG Treatment (BSL-1) ...*Request to Amend Registration to include a Sub study and SOP amendment:* **Approved on 06/05/2026.**

(IBC #36) Regulation of Inducible Nitric Oxide Synthase by Reactive Oxygen Species (BSL-2)...*Request for Continuation and to Amend Registration to include personnel:* **Approved on 06/15/26.**

(IBC #49) Signal Transduction and Angiogenesis (BSL-2)...*Request for Continuation and to Amend Registration to include personnel:* **Approved on 06/15/26.**

(IBC #162) Study of Myelination in Animals and Primary Cultures (BSL-2)...*Request for Continuation and to Amend Registration to include personnel:* **Approved on 06/15/26.**

(IBC #145) Pathological Glutamate Release in Stroke and Hyponatremia (BSL-2)...*Request to Amend Registration to include personnel:* **Approved on 06/26/26.**

Adjournment: The IBC Chair moved to adjourn the meeting at 2:46PM. The next meeting scheduled is for August 13, 2026 via Webex.